Loading company…
Xspray Pharma AB is a Swedish biopharmaceutical company developing protein kinase inhibitor formulations for cancer treatment.
Founded in 2003 in Sweden, Xspray Pharma develops enhanced formulations of existing protein kinase inhibitors (PKIs) for cancer, with Dasynoc (dasatinib) as its core product. Per Andersson is CEO. The company raised SEK 100 million in a Private Placement/Follow on as of October 2022, to strengthen its U.S. market presence and pipeline. In 2021 it reported zero revenue and EBITDA of SEK -10,385,675.2.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in